UK: A Quick Start Guide To EMIR: What You Need To Do And When

Keywords: EMIR, OTC derivatives, derivative contract

On 19 December 2012 the Commission adopted the majority of the subordinate legislation necessary to implement Regulation (EU) No 648/2012 of the European Parliament and of the Council of 4 July 2012 on OTC derivatives, central counterparties and trade repositories ("EMIR"). The majority of that legislation is likely to become law in or around March 20131 and some risk mitigation requirements will apply at that point. It appears that, although the first clearing obligation may not apply until the summer of 2014, the first reporting obligation may apply from 1 July 2013 and further risk mitigation obligations are likely to apply in or around September 2013. In addition, firms may need to make a number of notifications and applications for exemptions to the Financial Services Authority / Financial Conduct Authority in early 2013. At present, therefore, firms ought to be assessing whether they will be ready for EMIR to come into force. The quick start guide at page 4 sets out some of the things that firms should start to consider.

What does EMIR do?

1. EMIR:

(a) imposes clearing obligations on eligible derivatives (Article 4);

(b) imposes reporting obligations on all OTC derivatives (Article 9); and

(c) requires the implementation of new risk management standards, including operational processes and margining, for all OTC derivatives that are not cleared by a central clearing party ("CCP") (Article 11).

The Markets in Financial Instruments Regulation ("MiFIR") which is currently being negotiated will contain provisions regarding the trading of derivatives but indications are that it may not be adopted until Q4 2013. It should contain requirements that derivatives subject to the trading obligation can only be traded on regulated markets, multilateral trading facilities ("MTFs"), organised trading facilities ("OTFs") or approved third country venues.

2. EMIR contains the framework of the new regime but many of its obligations are dependent upon further detail being set out in subordinate legislation. The Commission has now adopted all the required subordinate legislation save that:

(a) related to margin and capital for non-centrally cleared trades (Article 11(3) and 11(4) EMIR); and

(b) specifying the contracts between third country counterparties that have a direct, substantial and foreseeable effect within the EU and the cases where it is necessary or appropriate to prevent the evasion of the provisions of EMIR (Article 4(4) and Article 11(14)).

In these respects further international coordination is necessary before EU rules can be developed.

Does it apply to me? (Scope)

3. EMIR applies to any entity established in the EU that is a legal counterparty to a derivative contract2, including interest rate, foreign exchange, equity, credit and commodity derivatives. It applies to EU firms even when trading with non-EU firms and has extraterritorial effect in some circumstances.

4. EMIR identifies two main categories of counterparty to a derivatives contract:

(a) 'financial counterparties', which includes financial institutions such as banks, insurers, MiFID investment firms, UCITS funds and, where appropriate, their management companies, occupational pension schemes and alternative investment funds managed by a manager authorised or registered under AIFMD 3; and

(b) 'non-financial counterparties', which covers any counterparty that is not classified as a financial counterparty, including entities not involved in financial services4.

5. The provisions in EMIR apply differently to non-financial counterparties whose positions in OTC derivative contracts exceed a clearing threshold ("qualifying non-financial counterparties") than to those whose positions do not. In general, qualifying non-financial counterparties are treated in the same way as financial counterparties. The provisions applicable to the different types of counterparty are as follows:

6. It is the responsibility of the non-financial counterparty to determine whether or not its positions exceed the clearing threshold and to notify the European Securities and Markets Authority ("ESMA") and the relevant national regulator if this is the case. In essence, hedging transactions are excluded from non-financial counterparties' calculation of their positions in OTC derivative contracts. The calculation of positions must include all OTC derivative contracts entered into by the non-financial counterparty itself or other non-financial counterparties within its group which are not objectively measurable as reducing risks directly related to the commercial activity or treasury financing activity of the counterparty or of its group5. The thresholds differ according to the type of derivative contract6 and are determined by taking into account the systemic relevance of the sum of the net positions and exposures per counterparty and per class of OTC derivative: they, and the criteria for establishing which contracts can be deemed to be for hedging purposes, are set out in the subordinate legislation adopted by the Commission on 19 December 20127.

EXEMPTIONS

7. There is not a complete exemption from EMIR but there are exemptions available from some of its requirements:

(a) intra-group transactions may qualify for exemptions from the clearing obligation and bilateral collateral requirements when certain conditions are met (Article 11(7) - (12));

(b) there is a three-year exemption from the clearing obligation available to certain transactions of pension schemes (Article 89(1)).

Pension schemes may, however, question the practical value of the exemption as they are not exempt from the risk mitigation requirements that are applied in respect of non-cleared trades.

8. In order to take advantage of these exemptions, counterparties must apply to their national regulators with evidence that they meet the relevant criteria. Information about the process for making notifications and the information that will need to be provided to the FSA will be available on the FSA website in early 2013.

EXTRATERRITORIAL EFFECT

9. The clearing obligation applies to contracts entered into by a financial counterparty or a qualifying non-financial counterparty in the EU and a third country entity provided that the third country entity would be subject to the clearing obligation if it were established in the EU8.

10. Both the clearing obligation and the risk mitigation requirements apply to contracts between third country entities that would be subject to the clearing obligation if they were established in the EU, provided that the contract has a "direct, substantial and foreseeable effect within the" EU "or where such an obligation is necessary or appropriate to prevent the evasion of any provisions of" EMIR9. In other words, the intention appears to be that entities engaged in OTC derivatives trading activities outside the EU should establish whether or not they would be a financial counterparty or qualifying non-financial counterparty if they were established in the EU. We await draft subordinate legislation on the contracts that have such a direct, substantial and foreseeable effect and the cases where it is necessary or appropriate to prevent evasion of EMIR but there has not been any further detail on how entities outside the EU should establish what class of counterparty they would be were they incorporated in the EU10.

11. The quick start guide set out on the following page is a non-exhaustive list of some of the things firms should start to consider. The issues included in this list are explained in more detail in the body of this note.

A quick start guide: What do I need to do and by when?

1. Are you are a financial counterparty ("FC") or a non-financial counterparty ("NFC")? If you are a NFC, are you a qualifying non-financial counterparty ("QNFC") or do your positions in OTC derivative contracts not exceed the clearing thresholds? If you are a QNFC, notify ESMA and your national regulator. (See paras 5 - 6.)

2. Will you be applying to your national regulator for exemption from any of the requirements of EMIR? (See paras 7 - 8.)

By approximately March 2013:

3. Which timely trade confirmation requirements apply to your contracts? Put in place procedures for the confirmation. (See para 14.)

4. You may delegate your obligations relating to trade confirmations but you will remain responsible for compliance*. Thus establish systems and procedures to provide the necessary confirmations or engage third party service providers to do this (and other tasks such as portfolio reconciliation) on your behalf.

5. If you are a FC, you need to set up procedures so that you have the ability to report unconfirmed trades that have been outstanding for more than five business days to your relevant national regulator on a monthly basis. (See para 15.)

6. FCs and QNFCs need to prepare, if you are not already doing so, to mark-to-market on a daily basis the value of outstanding OTC derivative contracts in accordance with the subordinate legislation. (See para 16.)

7. As regards reporting, do you have a relationship with a trade repository? If not, you need to consider establishing one before the first reporting obligation applies (possibly on 1 July 2013). If you plan to delegate your reporting obligation, you will need to ensure that your counterparties are willing to accept that responsibility or delegate that task to a third party. (See paras 19 - 22.)

By approximately September 2013:

8. Agree procedures and processes with your counterparties in relation to portfolio reconciliation and dispute resolution. (See para 17.)

9. Carry out portfolio reconciliations with your counterparties or delegate the task to a third party. (See para 17.)

10. If you have more than 500 outstanding bilateral OTC derivative contracts, put in place the required procedures on portfolio compression. (See para 17.)

11. Are you a member of clearing houses for all the cleared markets in which you are active? If not, can you become a clearing member? If not, you will need to enter into client clearing or indirect clearing arrangements with a broker before the first clearing obligation applies (possibly in summer 2014). (See paras 23 - 24.)

* See paragraph 88 of ESMA's "Final Report, Draft technical standards under Regulation (EU) No 648/2012 of the European Parliament and of the Council of 4 July 2012 on OTC derivatives, central counterparties and trade repositories" dated 27 September 2012 (ESMA/2012/600).

Risk mitigation requirements, including exchange of collateral

12. EMIR introduces new risk mitigation requirements for all uncleared OTC derivative trades, including timely confirmation of the terms of the contract (where possible by electronic means), portfolio reconciliation, portfolio compression and dispute resolution procedures. There are additional requirements for counterparties subject to the clearing obligation (financial counterparties and qualifying non-financial counterparties) which involve a daily valuation of outstanding contracts and having in place risk-management procedures that involve "the timely, accurate and appropriate segregated exchange of collateral"11. Financial counterparties will be subject to increased capital requirements if such collateral is not exchanged.

13. The risk mitigation requirements are not drafted so as to be dependent upon the coming into force of a clearing obligation. They are drafted so as to apply to OTC derivatives not cleared by a CCP, regardless of whether any CCP has been authorised to clear under the EMIR regime. The procedures and arrangements for timely confirmation, portfolio reconciliation, portfolio compression, dispute resolution and contract valuation, as well as the dates from which they will apply12, are set out the subordinate legislation adopted by the Commission on 19 December 201213. The timely confirmation and daily valuation requirements are likely to apply from around March 201314.

14. Until 31 August 2014, the requirements for timely confirmation differ depending on:

  • whether the relevant contract is a credit default swap or interest rate swap, or another type of derivative contract; and
  • whether the contract is concluded with a non-financial counterparty below the clearing threshold.

After 31 August 2014:

  • a contract between financial counterparties and qualifying non-financial counterparties must be confirmed by the end of the business day following its date of execution;
  • a contract with a non-financial counterparty below the clearing threshold must be confirmed by the end of the second business day following its date of execution.

15. In addition, there is a requirement for financial counterparties to have in place the procedures to report to their relevant national regulator on a monthly basis the number of unconfirmed trades that have been outstanding for more than five business days.

16. Financial counterparties and qualifying non-financial counterparties must mark-to-market on a daily basis the value of outstanding contracts. They may mark-to-model when market conditions prevent marking-to-market. Market conditions that prevent marking-to-market and the criteria for using a mark-to-model are set out in the subordinate legislation15.

17. The requirements relating to portfolio reconciliation, portfolio compression and dispute resolution16 are likely to apply in or around September 201317. The frequency of portfolio reconciliation depends on the number of outstanding contracts which are not centrally cleared and whether the counterparty is a financial counterparty, a qualifying non- financial counterparty or a non-financial counterparty below the clearing threshold. All counterparties with 500 or more outstanding contracts must have in place procedures so that they can determine regularly (at least twice a year) whether to conduct a portfolio compression exercise in order to reduce their counterparty credit risk. They must also be able to justify to their national regulator why they have not carried out a portfolio compression exercise.

18. The level and type of collateral to be exchanged and the segregation arrangements will be determined in subordinate legislation to be drafted jointly by the three European Supervisory Authorities and adopted by the Commission. The draft has been delayed to ensure consistency with the global development of international standards by the Working Group on Margining Requirements of the Basel Committee on Banking Supervision and the International Organisation of Securities Commissions. It is not yet clear when these standards will be developed and thus when the exchange of collateral will be mandated but it appears unlikely that this requirement will apply until after 2014.

The reporting obligation

19. The reporting obligation applies to all derivative contracts not just OTC contracts. Trade repositories need to be registered - or recognised if in a third country - by ESMA under EMIR before the reporting obligation can take effect. The dates for the start of the reporting obligations are set out in the subordinate legislation adopted by the Commission on 19 December 201218. They are as follows:

  • 1 July 2013 for credit and interest rate derivatives if a trade repository is registered for a particular derivative class by 1 April 2013 and 90 days after registration if there is no registered trade repository by 1 April 2013; and
  • 1 January 2014 for all other derivatives if a trade repository is registered for a particular derivative class by 1 October 2013 and 90 days after registration if there is no registered trade repository by 1 October 201319.

20. EMIR backdates the reporting obligation to derivative contracts which were entered into before 16 August 2012 and remained outstanding at that date and to derivative contracts entered into on or after 16 August 2012.

21. Once the reporting obligation has come into effect, both counterparties must report the details of every derivative contract they have concluded, modified or terminated within one working day of the conclusion, modification or termination. It is possible to delegate the reporting obligation or to make one report on behalf of both counterparties but each counterparty remains legally responsible for the report20.

22. The subordinate legislation adopted by the Commission on 19 December 2012 sets out the data that must be reported to trade repositories. Data to be reported includes the parties to the contract (or the beneficiary), the type of contract, its underlying maturity, notional value, price and the date of settlement, as well as any posted collateral and mark-to-market or mark-to-model valuations in some circumstances.

The clearing obligation

23. In essence, EMIR requires that OTC derivatives contracts which ESMA has determined are subject to a mandatory clearing obligation must be cleared by a CCP if the contract is between any combination of financial counterparties and non-financial counterparties whose rolling average position over 30 working days exceeds the thresholds. The clearing obligation does not apply to non-financial counterparties whose rolling average position over 30 working days does not exceed the thresholds.

24. The clearing obligation will not take effect until CCPs have been authorised - or recognised if in a third country - to clear under the new EMIR regime and the Commission has adopted a recommendation from ESMA regarding the class of OTC derivatives contracts which should be subject to the mandatory clearing obligation, the dates from which the obligation takes effect and the minimum remaining maturity of the OTC derivatives contracts which are subject to the obligation. Verena Ross, the Executive Director of ESMA, said in a speech on 4 December 2012 that, according to ESMA's projections, the first clearing obligation should apply from the summer of 201421.

Footnotes

1. The European Parliament and Council have a period of a month to exercise a right of scrutiny over certain pieces of the legislation ie until 20 January 2013. This period can be extended by another month and the Parliament, although not yet the Council, has requested such an extension ie until 20 February 2013. The legislation will be published in the Official Journal of the European Union immediately after the receipt of a notice of 'non-objection' from the European Parliament and Council and will mainly enter into force on the twentieth day thereafter, although some of the risk mitigation provisions shall apply 6 months thereafter. It on this basis that we estimate the dates of application of the risk mitigation requirements, although the dates may be brought forward if the Parliament does not use all of its extended period.

2 Defined as a financial instrument set out in points (4) to (10) of Section C of Annex I to Directive 2004/39 (MiFID).

3 See Article 2(8) EMIR.

4 See Article 2(9) EMIR.

5 See Article 10(1) - (3) EMIR.

6 A distinction is drawn between credit and equity derivatives on the one hand and interest rate, foreign exchange, commodity derivatives and all other derivatives on the other.

7 See Articles 10 and 11 of the Commission Delegated Regulation with regard to regulatory technical standards on indirect clearing arrangements, the clearing obligation, the public register, access to a trading venue, non-financial counterparties, risk mitigation techniques for OTC derivative contracts not cleared by a CCP.

8 See Article 4(1)(a)(iv) EMIR.

9 See Articles 4(1)(a)(v) and 11(12) EMIR. This provision mirrors similar language in Article 722(d) of the US Dodd-Frank Wall Street Reform and Consumer Protection Act 2010. Hence the need for international coordination on the cross-border effect of the regulations implementing the G20 agreement.

10 It is unlikely that national regulators will provide guidance on EU law.

11 Op. cit. at fn. 7 Article 11(3).

12 Op. cit. at fn. 7, Article 21.

13 Op. cit. at fn. 7.

14 They will apply from the day that the relevant subordinate legislation enters into force, that being the twentieth day after the regulation is published in the Official Journal of the EU.

15 Op. cit. at fn. 7, Articles 16 - 17.

16 Op. cit. at fn. 7, Articles 13 - 15.

17 They will apply six months after the entry into force of the subordinate legislation.

18 See Article 5 of Commission Implementing Regulation with regard to the format and frequency of trade reports to trade repositories.

19 On 19 December 2012 the Commission adopted subordinate legislation which set out the data that must be reported to trade repositories, the details required in an application for registration as a trade repository and the data to be published by trade repositories. A trade repository currently authorised or registered in the EU to collect and maintain records of derivatives must apply for authorisation or recognition within 6 months of the date of entry into force of the subordinate legislation. The clock is thus beginning to tick on the time at which the reporting obligation will take effect.

20 See Article 9(1) EMIR.

21 See "ESMA's role in markets reform", a speech by Verena Ross at the ICI Global Trading and Market Structure Conference. The speech is available on the ESMA website.

Previously published on 21 January 2013.

Visit us at mayerbrown.com

Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe – Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

© Copyright 2013. The Mayer Brown Practices. All rights reserved.

This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Reed Smith (Worldwide)
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Reed Smith (Worldwide)
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions